CALCIMIMETIC ADHERENCE AND PREFERENCE IN THE MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN EUROPE: A PILOT STUDY

被引：0

作者：

Louie, Karly ^{[1
]}

Nduka, Chidozie ^{[1
]}

Taylor, Jo ^{[2
]}

Hall, Matthew ^{[3
]}

Aucella, Filippo ^{[4
]}

Artero, Josep ^{[5
]}

Na, Pablo Ure ^{[6
]}

Labriola, Laura ^{[7
]}

Andersson, Per-Olof ^{[8
]}

Evenepoel, Pieter ^{[9
]}

Oliva, Juan Carlos Gonzalez ^{[10
]}

Pisoni, Ronald ^{[11
]}

Fouqueray, Bruno ^{[12
]}

Horne, Robert ^{[13
]}

机构：

[1] AMGEN Ltd, Ctr Observat Res, Uxbridge, Middx, England

[2] Dorset Cty Hosp, Dorchester, England

[3] Nottingham Univ Hosp, Nottingham, England

[4] Fdn IRCCS Casa Sollievo Sofferenza, Nephrol & Dialysis Unit, San Giovanni Rotondo, Italy

[5] Hosp Univ Girona, Serv Nefrol, Girona, Spain

[6] Necker Enfant Malad Hosp, Serv Nephrol Dialyse, Paris, France

[7] Catholic Univ Louvain, Clin Univ St Luc, Dept Nephrol, Brussels, Belgium

[8] Vrinnevisjukhuset, Med Kliniken, Norrkoping, Sweden

[9] Univ Hosp Leuven, Div Nephrol, Leuven, Belgium

[10] Fdn Privada Hosp Mollet, Barcelona, Spain

[11] Arbor Res Collaborat Hlth, Ann Arbor, MI USA

[12] Amgen GmbH, Rotkreuz, Switzerland

[13] UCL, Sch Pharm, London, England

来源：

NEPHROLOGY DIALYSIS TRANSPLANTATION | 2021年 / 36卷

关键词：

D O I：

暂无

中图分类号：

R3 [基础医学]; R4 [临床医学];

学科分类号：

1001 ; 1002 ; 100602 ;

摘要：

MO524

引用

页数：2

共 50 条

[31] The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism
Lindberg, JS
Moe, SM
Goodman, WG
Coburn, JW
Sprague, SM
Liu, W
Blaisdell, PW
Brenner, RM
Turner, SA
Martin, KJ
KIDNEY INTERNATIONAL, 2003, 63 (01) : 248 - 254
[32] Long-term-treatment of secondary hyperparathyroidism (HPT) with the calcimimetic cinacalcet HCl.
Moe, SM
Sprague, SM
Cunningham, J
Diueke, T
Adler, S
Rosansky, SJ
Albizem, MB
Guo, MD
Zani, V
Goodman, WG
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 463A - 464A
[33] Phase 3 study results demonstrate efficacy and safety of the calcimimetic cinacalcet HCI in hemodialysis patients with secondary hyperparathyroidism (HPT).
Block, GA
Martin, KJ
Turner, SA
Avram, MM
Hercz, G
Abu-Alfa, AK
Coyne, DW
Cohen, RM
Moe, SM
McCary, LC
Olson, KA
Goodman, WG
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 461A - 461A
[34] SURGICAL MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM
GORDON, HE
PASSARO, E
COBURN, JW
ARCHIVES OF SURGERY, 1972, 104 (04) : 520 - &
[35] Parathyroidectomy in the Management of Secondary Hyperparathyroidism
Lau, Wei Ling
Obi, Yoshitsugu
Kalantar-Zadeh, Kamyar
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2018, 13 (06): : 952 - 961
[36] Surgical Management of Secondary Hyperparathyroidism
Steinl, Gabrielle K.
Kuo, Jennifer H.
KIDNEY INTERNATIONAL REPORTS, 2021, 6 (02): : 254 - 264
[37] Surgical management of secondary hyperparathyroidism
Olson, JA
Leight, GS
ADVANCES IN RENAL REPLACEMENT THERAPY, 2002, 9 (03): : 209 - 218
[38] ADVANCES IN THE MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM
DIAZBUXO, JA
MCALISTER, JA
DIALYSIS & TRANSPLANTATION, 1984, 13 (01) : 14 - &
[39] Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism
Yu, Longchuan
Tomlinson, James E.
Alexander, Shawn T.
Hensley, Kelly
Han, Chun-Ya
Dwyer, Denise
Stolina, Marina
Dean, Charles, Jr.
Goodman, William G.
Richards, William G.
Li, Xiaodong
CALCIFIED TISSUE INTERNATIONAL, 2017, 101 (06) : 641 - 653
[40] Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism
Takashi Shigematsu
Masafumi Fukagawa
Keitaro Yokoyama
Takashi Akiba
Akifumi Fujii
Motoi Odani
Tadao Akizawa
Clinical and Experimental Nephrology, 2018, 22 : 426 - 436

← 1 2 3 4 5 →